{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T08:54:36Z","timestamp":1762505676509},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1016\/j.juro.2010.08.083","type":"journal-article","created":{"date-parts":[[2010,11,13]],"date-time":"2010-11-13T09:22:14Z","timestamp":1289640134000},"page":"67-71","source":"Crossref","is-referenced-by-count":22,"title":["Usefulness of the Spanish Urological Club for Oncological Treatment Scoring Model to Predict Nonmuscle Invasive Bladder Cancer Recurrence in Patients Treated With Intravesical Bacillus Calmette-Gu\u00e9rin Plus Interferon-\u03b1"],"prefix":"10.1097","volume":"185","author":[{"given":"Henry M.","family":"Rosevear","sequence":"first","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Lightfoot","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth G.","family":"Nepple","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Iowa, Iowa City, Iowa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2010.08.083_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib2","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib3","first-page":"281","article-title":"Bacillus Calmette-Guerin failures and beyond: contemporary management of non-muscle-invasive bladder cancer","volume":"10","author":"Grossman","year":"2008","journal-title":"Rev Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib5","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib6","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib7","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.juro.2009.07.148","article-title":"Editorial comment: predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated With bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Kamat","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2010.08.083_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.urolonc.2008.10.024","article-title":"Optimizing BCG therapy","volume":"27","author":"O'Donnell","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2010.08.083_bib10","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0022-5347(05)65469-9","article-title":"Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guerin treatment for superficial bladder cancer","volume":"167","author":"Saint","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib11","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0022-5347(05)00973-0","article-title":"The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy","volume":"175","author":"Joudi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib12","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.08.083_bib13","first-page":"947","article-title":"BCG immunotherapy for transitional-cell carcinoma in situ of the bladder","volume":"9","author":"Lamm","year":"1995","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.juro.2010.08.083_bib14","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)67523-4","article-title":"Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin","volume":"163","author":"Brake","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/j.1464-410X.2009.09137.x","article-title":"The effect of gender on response to bacillus Calmette-Guerin therapy for patients with non-muscle-invasive urothelial carcinoma of the bladder","volume":"106","author":"Boorjian","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.08.083_bib16","unstructured":"Rosevear HM, Lightfoot AJ and O'Donnell MA: Cancer recurrence disparities among racial and gender groups with non-muscle invasive bladder cancer (NMIBC) after intravesical bacillus Calmette-Guerin (BCG) and interferon alpha-2B therapy. Presented at annual meeting of Society for Urologic Oncology, Washington, D.C., December 8\u201310, 2009."},{"key":"10.1016\/j.juro.2010.08.083_bib17","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib18","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.5489\/cuaj.1194","article-title":"The optimal management of T1 high-grade bladder cancer","volume":"3","author":"Nepple","year":"2009","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.juro.2010.08.083_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0022-5347(05)67972-4","article-title":"Tumor progression and survival of patients with high grade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome","volume":"163","author":"Herr","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.08.083_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1464-410X.2008.08011.x","article-title":"The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer","volume":"103","author":"Streeper","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.08.083_bib21","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/jnci\/djn451","article-title":"Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer","volume":"101","author":"Margulis","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.juro.2010.08.083_bib22","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1464-410X.2009.08549.x","article-title":"Association of tumour necrosis factor-\u03b1 gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy","volume":"104","author":"Ahirwar","year":"2009","journal-title":"BJU Int"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710045246?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710045246?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2010.08.083","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:45:56Z","timestamp":1651196756000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2010.08.083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1016\/j.juro.2010.08.083"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2010.08.083","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}